ChangeBridge: Patent Grants - Pharma (A61K)

Juno Therapeutics Engineered T Cell Production Patent

The USPTO has granted Juno Therapeutics, Inc. a patent (US12577285B2) for a process to produce engineered T cells for cell therapy. The patent covers methods for pooling and stimulating T cells, introducing genetic material, and cultivating them for therapeutic use.

USPTO Patent Grant for Anti-IL-27 Antibodies

The USPTO has granted patent US12577299B2 to Surface Oncology, LLC for anti-IL-27 antibodies and their use in treating diseases, including cancer. The patent covers methods for administering these antibodies within specific dosage ranges.

USPTO Patent Grant for GRP78 Antibodies in Cancer Treatment

The USPTO has granted a patent (US12577301B2) to Rutgers, The State University of New Jersey for GRP78-binding antibodies. These antibodies are intended for the detection, diagnosis, and therapeutic treatment of cancers.

USPTO Patent Granted for HER4 Antibodies

The USPTO has granted patent US12577324B2 to INSERM for antibodies with specificity to HER4 and their uses. The patent covers fully human anti-HER4 single-chain variable antibody fragments (scFv) that bind to an epitope of the HER4 protein.

USPTO Grants Patent for PI3K-α Inhibitors to Relay Therapeutics

The USPTO has granted a patent (US12581252B2) to Relay Therapeutics, Inc. for substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors. The patent covers novel compounds and pharmaceutical compositions for treating disorders associated with PI3Kα signaling.